The Conversation (0)
SpeeDx Announces Distribution Agreement for PlexPCR(TM) and ResistancePlus(TM) Molecular Diagnostics Products With Goffin Molecular Technologies
Apr. 04, 2016 08:42AM PST
Medical Device InvestingGoffin’s Distribution Channels Will Allow Broader Availability and Accessibility of SpeeDx Diagnostics in the Benelux Markets SYDNEY, AUSTRALIA–(Marketwired – Apr 4, 2016) – SpeeDx Pty, Ltd. today announced a distribution agreement with Goffin Molecular Technologies B.V., a molecular diagnostic company based in the Netherlands. The agreement will open new channels for SpeeDx’ PlexPCR™ and unique …
Goffin’s Distribution Channels Will Allow Broader Availability and Accessibility of SpeeDx Diagnostics in the Benelux Markets
SYDNEY, AUSTRALIA–(Marketwired – Apr 4, 2016) – SpeeDx Pty, Ltd. today announced a distribution agreement with Goffin Molecular Technologies B.V., a molecular diagnostic company based in the Netherlands. The agreement will open new channels for SpeeDx’ PlexPCR™ and unique ResistancePlus™ multiplex real time polymerase chain reaction (qPCR) product lines to the Benelux market (Belgium, Netherlands and Luxembourg).
“The timing of this agreement aligns well with our near-term European launch plans to offer our PlexPCR infectious disease and ResistancePlus antibiotic resistance multiplex qPCR tests in the Benelux market,” said Colin Denver, Vice President of Sales & Marketing, SpeeDx. “Based on Goffin’s track record, we’re confident that this collaboration will rapidly increase our European presence in targeted molecular diagnostic markets.”
SpeeDx is committed to pioneering multiplex molecular diagnostic solutions for the global antibiotic resistance problem by offering tests that not only identify infectious disease pathogens, but provide actionable information on the antimicrobial resistance status of the pathogen. SpeeDx is initially focusing its ResistancePlus pipeline on sexually transmitted infections (STIs) such as Mycoplasma genitalium (MG) and Neisseria gonorrhoeae (NG) since both organisms have large and rapidly growing antibiotic resistance challenges.
Goffin Molecular Technologies offers a comprehensive line of molecular diagnostic products in the areas of infectious diseases, genetics, automation, consumables, reagents, instruments and pre-analytical treatments. Goffin’s qPCR kit for the determination of Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) is the company’s most successful assay in Europe. “We see our relationship with SpeeDx strengthening our core strategy as we continue to focus on new market needs,” said Eric van Vught, Director of Sales, Goffin Molecular Technologies.
About SpeeDx
Based in Sydney, Australia and founded in 2009, SpeeDx is a privately owned company that specializes in providing innovative multiplex real-time polymerase chain reaction (qPCR) and isothermal amplification solutions for clinical diagnostics. SpeeDx’s portfolio of market leading detection and priming technologies enable new healthcare paradigms that lead to improved delivery and reduced costs. SpeeDx has a proven track record of continued scientific discovery and strives to provide ever improving tools to the Clinical Diagnostic market. For more information on SpeeDx please see: https://www.speedx.com.au/
About PlexPCR and ResistancePlus
PlexPCR and ResistancePlus constitute multiplex qPCR kits for detection of infectious disease pathogens and antimicrobial resistance markers, respectively. Powered by the company’s proprietary PlexZyme and PlexPrime technologies, both product lines offer high multiplexing capability for better infectious disease management. All PlexPCR tests detect more pathogens and the ResistancePlus tests detect multiple genetic markers for antimicrobial resistance to provide more actionable information per test.
About Goffin Molecular Technologies
Based in the Netherlands, Goffin Molecular Technologies specializes in the distribution of molecular diagnostic equipment and products in the Benelux for a number of healthcare companies and in Europe for their own line of molecular diagnostic products. Goffin has developed intensive collaborations with customers, research centres, hospitals, manufacturers, suppliers and distributors that have enabled the company to quickly respond to the rapidly evolving needs of the molecular diagnostic market. After the development of several unique and reliable assays for sexually transmitted diseases, Goffin continues to focus on new market needs. For more information please see: https://www.goffinmoleculartechnologies.com/ .
“The timing of this agreement aligns well with our near-term European launch plans to offer our PlexPCR infectious disease and ResistancePlus antibiotic resistance multiplex qPCR tests in the Benelux market,” said Colin Denver, Vice President of Sales & Marketing, SpeeDx. “Based on Goffin’s track record, we’re confident that this collaboration will rapidly increase our European presence in targeted molecular diagnostic markets.”
SpeeDx is committed to pioneering multiplex molecular diagnostic solutions for the global antibiotic resistance problem by offering tests that not only identify infectious disease pathogens, but provide actionable information on the antimicrobial resistance status of the pathogen. SpeeDx is initially focusing its ResistancePlus pipeline on sexually transmitted infections (STIs) such as Mycoplasma genitalium (MG) and Neisseria gonorrhoeae (NG) since both organisms have large and rapidly growing antibiotic resistance challenges.
Goffin Molecular Technologies offers a comprehensive line of molecular diagnostic products in the areas of infectious diseases, genetics, automation, consumables, reagents, instruments and pre-analytical treatments. Goffin’s qPCR kit for the determination of Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) is the company’s most successful assay in Europe. “We see our relationship with SpeeDx strengthening our core strategy as we continue to focus on new market needs,” said Eric van Vught, Director of Sales, Goffin Molecular Technologies.
About SpeeDx
Based in Sydney, Australia and founded in 2009, SpeeDx is a privately owned company that specializes in providing innovative multiplex real-time polymerase chain reaction (qPCR) and isothermal amplification solutions for clinical diagnostics. SpeeDx’s portfolio of market leading detection and priming technologies enable new healthcare paradigms that lead to improved delivery and reduced costs. SpeeDx has a proven track record of continued scientific discovery and strives to provide ever improving tools to the Clinical Diagnostic market. For more information on SpeeDx please see: https://www.speedx.com.au/
About PlexPCR and ResistancePlus
PlexPCR and ResistancePlus constitute multiplex qPCR kits for detection of infectious disease pathogens and antimicrobial resistance markers, respectively. Powered by the company’s proprietary PlexZyme and PlexPrime technologies, both product lines offer high multiplexing capability for better infectious disease management. All PlexPCR tests detect more pathogens and the ResistancePlus tests detect multiple genetic markers for antimicrobial resistance to provide more actionable information per test.
About Goffin Molecular Technologies
Based in the Netherlands, Goffin Molecular Technologies specializes in the distribution of molecular diagnostic equipment and products in the Benelux for a number of healthcare companies and in Europe for their own line of molecular diagnostic products. Goffin has developed intensive collaborations with customers, research centres, hospitals, manufacturers, suppliers and distributors that have enabled the company to quickly respond to the rapidly evolving needs of the molecular diagnostic market. After the development of several unique and reliable assays for sexually transmitted diseases, Goffin continues to focus on new market needs. For more information please see: https://www.goffinmoleculartechnologies.com/ .